
George M. Eliopoulos, M.D.
Editor
- Professor of Medicine, Harvard Medical School (2001-Present)
- Physician, Infectious Diseases, Beth Israel Deaconess Medical Center, Boston, MA (1982-Present)
Area of Special Interest
- Antimicrobial Resistance
- Antimicrobial Activity
Professional Recognitions & Appointments
- Former Editor-in-Chief of the American Society for Microbiology’s Antimicrobial Agents and Chemotherapy
- Advisor - Antimicrobial Susceptibility Testing Subcommittee of the Clinical and Laboratory Standards Institute
- Fellow - Infectious Diseases Society of America
- Fellow - American College of Physicians
Publication Highlights
Over 160 publications including:
- Susceptibility of Multidrug-Resistant Gram-Negative Urine Isolates to Oral Antibiotics. Antimicrobial Agents and Chemotherapy – May 2016
- Impact of daptomycin resistance on Staphylococcus aureus virulence. Virulence – 2015
- Serine/threonine phosphatase Stp1 contributes to reduced susceptibility to vancomycin and virulence in Staphylococcus aureus. The Journal of Infectious Diseases – June 2012
- Whole genome characterization of the mechanisms of daptomycin resistance in clinical and laboratory derived isolates of Staphylococcus aureus. PLoS One - January 2012
Education
- Harvard University (A.B)
- Harvard Medical School (Medical School)
- Columbia-Presbyterian Medical Center (Residency)
- Massachusetts General Hospital (Fellowship)
- Harvard Medical School (Fellowship Robert C. Moellering, Jr., M.D.)
Disclosures
- Nabriva Therapeutics, 2018
- Melinta Therapeutics, 2018
- Zavante Therapeutics, 2017
- Taxis Pharmaceuticals, 2016